Adverse effects beyond 56 weeks of study treatment: grade 3 or higher events and SAEs
| Event, grade ≥3 . | Event frequency (N = 17) (%) . |
|---|---|
| Neutropenia | 1 (6) |
| Hypertension | 1 (6) |
| Cutaneous neoplasm | 1 (6) |
| Therapy-related myelodysplastic syndrome | 1 (6)∗ |
| Glioblastoma multiforme | 1 (6) |
| Metastatic small cell lung cancer | 1 (6) |
| Febrile neutropenia | 1 (6)∗ |
| Sinusitis | 1 (6)∗ |
| Urosepsis | 1 (6)∗ |
| Infectious enterocolitis | 1 (6)∗ |
| Lung infection | 2 (12)∗ |
| Diarrhea | 3 (17)† |
| Event, grade ≥3 . | Event frequency (N = 17) (%) . |
|---|---|
| Neutropenia | 1 (6) |
| Hypertension | 1 (6) |
| Cutaneous neoplasm | 1 (6) |
| Therapy-related myelodysplastic syndrome | 1 (6)∗ |
| Glioblastoma multiforme | 1 (6) |
| Metastatic small cell lung cancer | 1 (6) |
| Febrile neutropenia | 1 (6)∗ |
| Sinusitis | 1 (6)∗ |
| Urosepsis | 1 (6)∗ |
| Infectious enterocolitis | 1 (6)∗ |
| Lung infection | 2 (12)∗ |
| Diarrhea | 3 (17)† |